Endogenous prostaglandin D2 and its metabolites protect the heart against ischemia-reperfusion injury by activating Nrf2

Yoshinori Katsumata, Ken Shinmura, Yuki Sugiura, Shugo Tohyama, Tomohiro Matsuhashi, Hideyuki Ito, Xiaoxiang Yan, Kentaro Ito, Shinsuke Yuasa, Masaki Ieda, Yoshihiro Urade, Makoto Suematsu, Keiichi Fukuda, Motoaki Sano

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

We recently demonstrated that glucocorticoids markedly upregulate the expression of cyclooxygenase-2 in cardiomyocytes and protect hearts from ischemia-reperfusion (I/R) injury by activating lipocalin-type prostaglandin D (PGD) synthase (L-PGDS)-derived PGD2 biosynthesis. We examined a downstream mechanism of cardioprotection elicited by PGD2 biosynthesis. Acute PGD2 treatment did not protect hearts against I/R injury. We then speculated that PGD2 and its metabolite 15-deoxy-Δ12,14-PGJ2 activate gene expression networks to mediate the glucocorticoid-mediated cardioprotection. Using an unbiased approach, we identified that glucocorticoids induce a number of well-known erythroid-derived 2-like 2 (Nrf2) target genes in the heart in an L-PGDS-dependent manner and that the cardioprotective effect of glucocorticoids against I/R injury was not seen in Nrf2-knockout hearts. We showed relatively low expression of PGD2 receptors (ie, DP1 and DP2) in the heart but abundant expression of PGF2α receptor (FP), which binds PGF2α and PGD2 with equal affinity. Glucocorticoids also failed to induce the expression of L-PGDS-dependent Nrf2 target genes in FP-knockout hearts. PGD2 acted through its metabolite 15-deoxy-Δ12,14-PGJ2 in the heart as evidenced by the glucocorticoid-mediated activation of peroxisome proliferator-activated receptor-γ. In turn, glucocorticoids failed to induce the expression of L-PGDS-dependent Nrf2 target genes in hearts pretreated with peroxisome proliferator-activated receptor-γ antagonist GW9662, and glucocorticoid-mediated cardioprotection against I/R injury was compromised in FP-knockout mice and GW9662-treated mice. In conclusion, PGD2 protects heart against I/R injury by activating Nrf2 predominantly via FP receptor. In addition, we propose activation of peroxisome proliferator-activated receptor-γ by the dehydrated metabolite of PGD2 (15-deoxy-Δ12,14- PGJ2) as another mechanism by which glucocorticoids induce cardioprotection.

Original languageEnglish
Pages (from-to)80-87
Number of pages8
JournalHypertension
Volume63
Issue number1
DOIs
Publication statusPublished - 2014 Jan

Fingerprint

Prostaglandin D2
Reperfusion Injury
Glucocorticoids
Peroxisome Proliferator-Activated Receptors
Dinoprost
prostaglandin R2 D-isomerase
Genes
Lipocalins
Gene Regulatory Networks
Cyclooxygenase 2
Cardiac Myocytes
Knockout Mice
Up-Regulation
Gene Expression

Keywords

  • 15-deoxyprostaglandin J2
  • Nrf2
  • Oxidative stress
  • PPAR gamma
  • Prostaglandin D2
  • Prostaglandin F receptor

ASJC Scopus subject areas

  • Internal Medicine
  • Medicine(all)

Cite this

Endogenous prostaglandin D2 and its metabolites protect the heart against ischemia-reperfusion injury by activating Nrf2. / Katsumata, Yoshinori; Shinmura, Ken; Sugiura, Yuki; Tohyama, Shugo; Matsuhashi, Tomohiro; Ito, Hideyuki; Yan, Xiaoxiang; Ito, Kentaro; Yuasa, Shinsuke; Ieda, Masaki; Urade, Yoshihiro; Suematsu, Makoto; Fukuda, Keiichi; Sano, Motoaki.

In: Hypertension, Vol. 63, No. 1, 01.2014, p. 80-87.

Research output: Contribution to journalArticle

Katsumata, Yoshinori ; Shinmura, Ken ; Sugiura, Yuki ; Tohyama, Shugo ; Matsuhashi, Tomohiro ; Ito, Hideyuki ; Yan, Xiaoxiang ; Ito, Kentaro ; Yuasa, Shinsuke ; Ieda, Masaki ; Urade, Yoshihiro ; Suematsu, Makoto ; Fukuda, Keiichi ; Sano, Motoaki. / Endogenous prostaglandin D2 and its metabolites protect the heart against ischemia-reperfusion injury by activating Nrf2. In: Hypertension. 2014 ; Vol. 63, No. 1. pp. 80-87.
@article{8e573abb11f447f9909ebe46ac16f6fe,
title = "Endogenous prostaglandin D2 and its metabolites protect the heart against ischemia-reperfusion injury by activating Nrf2",
abstract = "We recently demonstrated that glucocorticoids markedly upregulate the expression of cyclooxygenase-2 in cardiomyocytes and protect hearts from ischemia-reperfusion (I/R) injury by activating lipocalin-type prostaglandin D (PGD) synthase (L-PGDS)-derived PGD2 biosynthesis. We examined a downstream mechanism of cardioprotection elicited by PGD2 biosynthesis. Acute PGD2 treatment did not protect hearts against I/R injury. We then speculated that PGD2 and its metabolite 15-deoxy-Δ12,14-PGJ2 activate gene expression networks to mediate the glucocorticoid-mediated cardioprotection. Using an unbiased approach, we identified that glucocorticoids induce a number of well-known erythroid-derived 2-like 2 (Nrf2) target genes in the heart in an L-PGDS-dependent manner and that the cardioprotective effect of glucocorticoids against I/R injury was not seen in Nrf2-knockout hearts. We showed relatively low expression of PGD2 receptors (ie, DP1 and DP2) in the heart but abundant expression of PGF2α receptor (FP), which binds PGF2α and PGD2 with equal affinity. Glucocorticoids also failed to induce the expression of L-PGDS-dependent Nrf2 target genes in FP-knockout hearts. PGD2 acted through its metabolite 15-deoxy-Δ12,14-PGJ2 in the heart as evidenced by the glucocorticoid-mediated activation of peroxisome proliferator-activated receptor-γ. In turn, glucocorticoids failed to induce the expression of L-PGDS-dependent Nrf2 target genes in hearts pretreated with peroxisome proliferator-activated receptor-γ antagonist GW9662, and glucocorticoid-mediated cardioprotection against I/R injury was compromised in FP-knockout mice and GW9662-treated mice. In conclusion, PGD2 protects heart against I/R injury by activating Nrf2 predominantly via FP receptor. In addition, we propose activation of peroxisome proliferator-activated receptor-γ by the dehydrated metabolite of PGD2 (15-deoxy-Δ12,14- PGJ2) as another mechanism by which glucocorticoids induce cardioprotection.",
keywords = "15-deoxyprostaglandin J2, Nrf2, Oxidative stress, PPAR gamma, Prostaglandin D2, Prostaglandin F receptor",
author = "Yoshinori Katsumata and Ken Shinmura and Yuki Sugiura and Shugo Tohyama and Tomohiro Matsuhashi and Hideyuki Ito and Xiaoxiang Yan and Kentaro Ito and Shinsuke Yuasa and Masaki Ieda and Yoshihiro Urade and Makoto Suematsu and Keiichi Fukuda and Motoaki Sano",
year = "2014",
month = "1",
doi = "10.1161/HYPERTENSIONAHA.113.01639",
language = "English",
volume = "63",
pages = "80--87",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Endogenous prostaglandin D2 and its metabolites protect the heart against ischemia-reperfusion injury by activating Nrf2

AU - Katsumata, Yoshinori

AU - Shinmura, Ken

AU - Sugiura, Yuki

AU - Tohyama, Shugo

AU - Matsuhashi, Tomohiro

AU - Ito, Hideyuki

AU - Yan, Xiaoxiang

AU - Ito, Kentaro

AU - Yuasa, Shinsuke

AU - Ieda, Masaki

AU - Urade, Yoshihiro

AU - Suematsu, Makoto

AU - Fukuda, Keiichi

AU - Sano, Motoaki

PY - 2014/1

Y1 - 2014/1

N2 - We recently demonstrated that glucocorticoids markedly upregulate the expression of cyclooxygenase-2 in cardiomyocytes and protect hearts from ischemia-reperfusion (I/R) injury by activating lipocalin-type prostaglandin D (PGD) synthase (L-PGDS)-derived PGD2 biosynthesis. We examined a downstream mechanism of cardioprotection elicited by PGD2 biosynthesis. Acute PGD2 treatment did not protect hearts against I/R injury. We then speculated that PGD2 and its metabolite 15-deoxy-Δ12,14-PGJ2 activate gene expression networks to mediate the glucocorticoid-mediated cardioprotection. Using an unbiased approach, we identified that glucocorticoids induce a number of well-known erythroid-derived 2-like 2 (Nrf2) target genes in the heart in an L-PGDS-dependent manner and that the cardioprotective effect of glucocorticoids against I/R injury was not seen in Nrf2-knockout hearts. We showed relatively low expression of PGD2 receptors (ie, DP1 and DP2) in the heart but abundant expression of PGF2α receptor (FP), which binds PGF2α and PGD2 with equal affinity. Glucocorticoids also failed to induce the expression of L-PGDS-dependent Nrf2 target genes in FP-knockout hearts. PGD2 acted through its metabolite 15-deoxy-Δ12,14-PGJ2 in the heart as evidenced by the glucocorticoid-mediated activation of peroxisome proliferator-activated receptor-γ. In turn, glucocorticoids failed to induce the expression of L-PGDS-dependent Nrf2 target genes in hearts pretreated with peroxisome proliferator-activated receptor-γ antagonist GW9662, and glucocorticoid-mediated cardioprotection against I/R injury was compromised in FP-knockout mice and GW9662-treated mice. In conclusion, PGD2 protects heart against I/R injury by activating Nrf2 predominantly via FP receptor. In addition, we propose activation of peroxisome proliferator-activated receptor-γ by the dehydrated metabolite of PGD2 (15-deoxy-Δ12,14- PGJ2) as another mechanism by which glucocorticoids induce cardioprotection.

AB - We recently demonstrated that glucocorticoids markedly upregulate the expression of cyclooxygenase-2 in cardiomyocytes and protect hearts from ischemia-reperfusion (I/R) injury by activating lipocalin-type prostaglandin D (PGD) synthase (L-PGDS)-derived PGD2 biosynthesis. We examined a downstream mechanism of cardioprotection elicited by PGD2 biosynthesis. Acute PGD2 treatment did not protect hearts against I/R injury. We then speculated that PGD2 and its metabolite 15-deoxy-Δ12,14-PGJ2 activate gene expression networks to mediate the glucocorticoid-mediated cardioprotection. Using an unbiased approach, we identified that glucocorticoids induce a number of well-known erythroid-derived 2-like 2 (Nrf2) target genes in the heart in an L-PGDS-dependent manner and that the cardioprotective effect of glucocorticoids against I/R injury was not seen in Nrf2-knockout hearts. We showed relatively low expression of PGD2 receptors (ie, DP1 and DP2) in the heart but abundant expression of PGF2α receptor (FP), which binds PGF2α and PGD2 with equal affinity. Glucocorticoids also failed to induce the expression of L-PGDS-dependent Nrf2 target genes in FP-knockout hearts. PGD2 acted through its metabolite 15-deoxy-Δ12,14-PGJ2 in the heart as evidenced by the glucocorticoid-mediated activation of peroxisome proliferator-activated receptor-γ. In turn, glucocorticoids failed to induce the expression of L-PGDS-dependent Nrf2 target genes in hearts pretreated with peroxisome proliferator-activated receptor-γ antagonist GW9662, and glucocorticoid-mediated cardioprotection against I/R injury was compromised in FP-knockout mice and GW9662-treated mice. In conclusion, PGD2 protects heart against I/R injury by activating Nrf2 predominantly via FP receptor. In addition, we propose activation of peroxisome proliferator-activated receptor-γ by the dehydrated metabolite of PGD2 (15-deoxy-Δ12,14- PGJ2) as another mechanism by which glucocorticoids induce cardioprotection.

KW - 15-deoxyprostaglandin J2

KW - Nrf2

KW - Oxidative stress

KW - PPAR gamma

KW - Prostaglandin D2

KW - Prostaglandin F receptor

UR - http://www.scopus.com/inward/record.url?scp=84891633265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891633265&partnerID=8YFLogxK

U2 - 10.1161/HYPERTENSIONAHA.113.01639

DO - 10.1161/HYPERTENSIONAHA.113.01639

M3 - Article

C2 - 24101662

AN - SCOPUS:84891633265

VL - 63

SP - 80

EP - 87

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 1

ER -